AROAPOC3-3009
Brief description of study
Requesting a reliance agreement with an external IRB. The purpose of this double-blind, placebo-controlled trial is to evaluate the safety and efficacy of treatment with plozasiran on the reduction of fasting serum TG from Baseline in subjects with Hypertriglyceridemia who have fasting TG levels between 150 mg/dL and 499 mg/dL.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
